Beta adrenoceptor blockade has become one of the major therapeutic interventions in the medical management of ischaemic heart disease over the last 15 years. A number of beta adrenóceptor blockers have been developed with differing pharmacological properties including cardioselectivity and intrinsic sympathomimetic activity (ISA). The relevance of this latter property has been in some doubt. A number of reports suggest that ISA confers haemodynamic benefits although there does not appear to be any clear therapeutic advantage. In addition it would appear that patients with severe or rest angina might benefit more from a pure beta antagonist rather than one with ISA when the beta blocker is used as monotherapy, but this situation rarely arises.
This paper reviews and assesses the value of treatment of ischaemic heart disease with beta blockers possessing intrinsic sympathomimetic activity.
MoranNCPerkinsME. Adrenergic blockade of the mammalian heart by a dichloro analogue of isoproterenol. J Pharmacol Exp Ther1958; 124: 223–237.
2.
GloverWEGreenfieldADMShanksRG. Effects of dichloroisoprenaline on the peripheral vascular responses adrenaline in man. Br J Pharmacol1962; 19: 235–244.
3.
DreselPE. Blockade of some cardiac actions of adrenaline by dichloroisoproterenol. Can J Biochem1960; 38: 375–381.
4.
FrishmanWSilvermanR. Clinical pharmacology of the new beta adrenergic blocking drugs. 3. Comparative clinical experiences and new therapeutic applications. Am Heart J1979; 98: 119–131.
5.
RealeAMotoleseM. Partial agonist activity of beta blocking agents and cardiac performance: A review. Eur Heart J1981; 2: 245–251.
6.
ShanksRG. Partial agonist activity of beta blocking drugs. Review of a review. Eur Heart J1981; 2: 253–255.
7.
FrishmanWH. B-Adrenoceptor antagonists: New drugs and new indications. N Engl J Med1981; 305: 500–506.
8.
KostisJBFrishmanWHosierMHThorsenNLGonasunLWeinsteinJ. Treatment of angina pectoris with Pindolol: The significance of intrinsic sympathomimetic activity of beta blockers. Am Heart J1982; 104; 496–504.
9.
ThadaniUDavidsonCSingletonWTaylorSH. Comparison of the immediate effects of five B-adrenoceptor blocking drugs with different ancillary properties in angina pectoris. N Engl J Med1979; 300: 750–755.
10.
GonasunLM. Antihypertensive effects of Pindolol. Am Heart J1982; 104: 374–87.
11.
FrishmanWDavisRStromJClinical pharmacology of the new beta-adrenergic blocking drugs. 5. Pindolol (LB-46) therapy for supraventricular arrhythmia: A viable alternative to Propranolol in patients with bronchospasm. Am Heart J1979; 98: 393–398.
12.
AronowWSVyeyamaRR. Treatment of arrhythmias with Pindolol. Clin Pharmacol Ther1972; 13: 15–22.
13.
PodridPJLownB. Pindolol for ventricular arrhythmia. Am Heart J1982; 104: 491–496.
14.
RealeANigriAGioffrePAMotoleseM. Acute influence of beta blocking agents upon left heart haemodynamics at rest and during exercise in patients with coronary disease. Eur J Cardiol1979; 9: 101–109.
15.
ClarkBJMenningerKBertholetA. Pindolol — The pharmacology of a patient agonist. Br J Clin Pharmacol1982; 13 (Suppl. 2): 149s–158s.
16.
AhlquistRP. Present state of ∝ and B-adrenergic drugs. II The adrenergic blocking agents. Am Heart J1976; 92: 804–807.
SvendsenTLHartlingOJTrap-JensenJMcNairABliddalJ. Adrenergic beta-receptor blockade: Haemodynamic importance of intrinsic sympathomimetic activity at rest. Clin Pharmacol Ther1981; 29: 711–718.
23.
FranciosaJAJohnsonSMTobianLJ. Haemodynamic effects of Oxprenolol and Propranolol in hypertension. Clin Pharmacol Ther1979; 26: 676–681.
24.
Man in't VeldAJBoomsmaFSchalekampMADH. Effects of B-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy. Br J Clin Pharmacol1982; 13 (Suppl.): 367s–374s.
25.
Man in't VeldAJSchalekampMADH. Pindolol acts as B-adrenoceptor agonist in orthostatic hypotension: Therapeutic implications. Br Med J1981; 282: 929–931.
26.
TaylorSHSilkeBLeePS. Intravenous beta-blockade in coronary heart disease. Is cardioselectivity or intrinsic sympathomimetic activity haemodynamically useful? N Eng J Med1982; 306: 631–635.
27.
HahnBStrauerBE. The influence of B-adrenoceptor blockade on left ventricular function. Br J Clin Pharmacol1982; 13 (Suppl. 2): 305s–307s.
28.
HeikkilaJNieminenMS. Cardiac safety of acute beta blockade: Intrinsic sympathomimetic activity is superior to beta-1-selectivity. Am Heart J1982; 104: 464–472.
29.
SvendsenTLCarlesenJEHartlingO. A comparison of the acute haemodynamic effects of Propranolol and Pindolol at rest and during supine exercise in man. Clin Sci1980; 59 (Suppl.): 465s–468s.
30.
DunerHPernowB. Haemodynamic effects of B-receptor blocking agents and digitalis in ischaemic heart disease with angina pectoris. Acta Med Scand1973; 194: 517–523.
31.
HuntDSlomanGClarkRM. Effects of beta-adrenergic blockade on the systolic time intervals. Am J Med Sci1970; 259: 97–113.
32.
FrishmanWKostisJStromJ. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of Pindolol and Propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J1979; 98: 526–535.
33.
TsukiyamaHOtsukaKMiyamotoK. Haemodynamic effects of beta-adrenergic blockade with Pindolol, Oxprenolol, Propranolol and Byletolol Hydrochloride in essential hypertension. Jpn Circ J1976; 40: 655–664.
34.
ManyariDEKostukWJCarruthersCJohnstonDJPurvesRT. Pindolol and Propranolol in patients with angina pectoris and normal or near-normal ventricular function. Am J Cardiol1983; 51: 427–433.
35.
MarshallRCBergerHJRedutoLACohenLSGottschalkAZaretBL. Assessment of cardiac performance with quantitative radionuclide angiocardiography. Effects of oral Propranolol on global and regional left ventricular function in coronary artery disease. Circulation1978; 58: 808–814.
36.
BattlerARossJJrSlutskyRPfistererMAshburnWFroelicherV. Improvement of exercise induced left ventricular dysfunction with oral Propranolol in patients with coronary heart disease. Am J Cardiol1979; 44: 318–324.
37.
MarshallRCWisenbergGSchelbertHRHenzeE. Effect of oral Propranolol on rest, exercise and post exercise left ventricular performance in normal subjects and patients with coronary artery disease. Circulation1981; 63: 572–583.
38.
RainwaterJSteelePKirchDLe FreeMJensenDVogelR. Effect of Propranolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation1982; 65: 77–81.
39.
RosenthalJKaiserHRaschigA. Treatment of hypertension with a beta-adrenoceptor blocker: A multicentre trial with Pindolol. Br J Clin Pract1979; 33: 165–174.
40.
McNeilJJLouisWJ. A double-blind crossover comparison of Pindolol, Metoprolol, Atenolol and Labetolol in mild to moderate hypertension. Br J Clin Pharmacol1979; 8 (Suppl. 2): 163s–166s.
41.
OuyyumiAAWrightCMockusLFoxKM. Effect of partial agonist activity in beta blockers in severe angina pectoris: A double blind comparison of Pindolol and Atenolol. Br Med J1984; 289: 951–953.
42.
ThadaniUDavidsonCSingletonWTaylorS. Comparison of five beta adrenoceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med1980; 68: 243–250.
43.
BoakesAJPrichardBNC. The effect of AH5158, Pindolol, Propranolol and D-propranolol acute exercise tolerance in angina pectoris. Br J Pharmacol1973;47:673P–674P.
JacksonGAtkinsonLOramS. Double-blind comparison of Timolol, Propranolol, Practolol and placebo in the treatment of angina pectoris. Br Med J1975; 1: 708–712.
46.
AdolfssonLAreskognHFurbergC. Synergistic effects of a new beta-adrenergic blocker (Pindolol) and Isosorbide Dinitrate during exercise in patients with coronary insufficiency. Eur J Clin Pharmacol1972; 5: 37–43.
47.
StorsteinL. The effect of Pindolol and Isosorbide Dinitrate and their combination on exercise tolerance and ECG changes in angina pectoris. Acta Med Scand1981; 209: 357–362.
48.
AndersonSDByePTCPerryCPHamorCPTheobaldCNybergB. Limitations of work performance in normal adult males in the presence of beta adrenergic blockade. Aust NZ J Med1979; 9: 515–520.
49.
FranciosaJAJohnsonSMTobianLJ. Exercise performance in mildly hypertensive patients. Impairment by Propranolol but not Oxprenolol. Chest1980; 78: 291–299.
